Table 1.
Characteristics of DLBCL survivors (N = 2600) and matched general population comparison group (N = 13 000) in Hong Kong, 2000-2018
| Characteristic | All lymphoma patients (N = 2600) | Normal comparison group (n = 13 000) | P | Lymphoma patients categorized by CVD status (N = 2600) | P | |
|---|---|---|---|---|---|---|
| CVD (n = 175) | No CVD (n = 2425) | |||||
| Patient factors | ||||||
| Median age at lymphoma diagnosis (IQR), y | 63 (53-73) | 63 (54-72) | —* | 70 (62-79) | 62 (52-72) | <.001 |
| Sex | —* | .875 | ||||
| Male | 1456 (56.0) | 7 280 (56.0) | 99 (56.6) | 1357 (56.0) | ||
| Female | 1144 (44.0) | 5 720 (44.0) | 76 (43.4) | 1068 (44.0) | ||
| Race/ethnicity | .001 | .068 | ||||
| Chinese | 2484 (95.5) | 12 586 (96.8) | 172 (98.3) | 2312 (95.3) | ||
| Non-Chinese | 116 (4.5) | 414 (3.2) | 3 (1.7) | 113 (4.7) | ||
| RCS comorbidity scores | <.001 | <.001 | ||||
| 0 | 1710 (65.8) | 8 871 (68.2) | 69 (39.4) | 1641 (67.7) | ||
| 1 | 664 (25.5) | 2 631 (20.2) | 61 (34.9) | 603 (24.9) | ||
| ≥2 | 226 (8.7) | 1 498 (11.5) | 45 (25.7) | 181 (7.5) | ||
| Median follow-up time for alive patients (IQR), y | 6.8 (3.6-10.5) | 7.8 (4.4-10.9) | <.001 | 5.3 (1.9-7.5) | 6.9 (3.6-10.6) | <.001 |
| Year of diagnosis | — | <.001 | ||||
| 2000-2004 | 398 (15.3) | — | 37 (21.1) | 361 (14.9) | ||
| 2005-2009 | 697 (26.8) | — | 68 (38.9) | 629 (25.9) | ||
| 2010-2014 | 870 (33.5) | — | 51 (29.1) | 819 (33.8) | ||
| 2015-2018 | 635 (24.4) | — | 19 (10.9) | 616 (25.4) | ||
| Fee waiver recipients (surrogate for lower socioeconomic status) | 200 (7.7) | 3 186 (24.5) | <.001 | 22 (12.6) | 178 (7.3) | .012 |
| COPD or smoker | 645 (24.8) | 5 662 (43.6) | <.001 | 72 (41.1) | 573 (23.6) | <.001 |
| Alcohol-related diseases | 18 (0.7) | 98 (0.8) | .739 | 0 (0.0) | 18 (0.7) | .253 |
| Diabetes mellitus | 598 (23.0) | 4 708 (36.2) | <.001 | 71 (40.6) | 527 (21.7) | <.001 |
| Hypertension | 1797 (69.1) | 10 393 (80.0) | <.001 | 173 (98.9) | 1624 (67.0) | <.001 |
| Dyslipidemia/hyperlipidemia | 586 (22.5) | 6 349 (48.8) | <.001 | 84 (48.0) | 502 (20.7) | <.001 |
| Anxiety or depressive disorders | 436 (16.8) | 3 435 (26.4) | <.001 | 37 (21.1) | 399 (16.4) | .109 |
| Atrial fibrillation | 31 (1.2) | 514 (4.0) | <.001 | 7 (4.0) | 24 (1.0) | <.001 |
| ACE inhibitor use | 574 (22.1) | 5 269 (40.5) | <.001 | 102 (58.3) | 472 (19.5) | <.001 |
| Beta blocker use | 792 (30.5) | 5 436 (41.8) | <.001 | 119 (68.0) | 673 (27.8) | <.001 |
| Aspirin use | 602 (23.2) | 5 266 (40.5) | <.001 | 131 (74.9) | 471 (19.4) | <.001 |
| Treatment factors | ||||||
| Chemotherapy | — | — | .761 | |||
| Regimens containing doxorubicin | ||||||
| >500 mg | 166 (6.4) | — | 13 (7.4) | 153 (6.3) | ||
| ≤500 mg | 699 (26.9) | — | 44 (25.2) | 655 (27.0) | ||
| Non-doxorubicin regimens | 1735 (66.7) | — | 118 (67.4) | 1617 (66.7) | ||
| RT | 308 (11.9) | — | — | 25 (14.3) | 283 (11.7) | .301 |
| Rituximab | 1980 (76.2) | — | — | 126 (72.0) | 49 (28.0) | .182 |
All data are no. (%) unless otherwise indicated.
*
People in the normal comparison group were sex- and age-matched to lymphoma patients.